Sol-Gel Technologies ROE 2016-2024 | SLGL
Current and historical return on equity (ROE) values for Sol-Gel Technologies (SLGL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Sol-Gel Technologies ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-12-31 |
$-0.01B |
$0.03B |
-30.30% |
| 2024-09-30 |
$-0.01B |
$0.04B |
-25.35% |
| 2024-06-30 |
$-0.02B |
$0.04B |
-40.00% |
| 2024-03-31 |
$-0.02B |
$0.03B |
-56.44% |
| 2023-12-31 |
$-0.03B |
$0.04B |
-64.37% |
| 2023-09-30 |
$-0.03B |
$0.04B |
-65.54% |
| 2023-06-30 |
$-0.03B |
$0.05B |
-57.46% |
| 2023-03-31 |
$-0.02B |
$0.04B |
-43.72% |
| 2022-12-31 |
$-0.02B |
$0.04B |
-31.75% |
| 2022-09-30 |
$0.01B |
$0.05B |
9.85% |
| 2022-06-30 |
$0.01B |
$0.05B |
18.27% |
| 2022-03-31 |
$0.00B |
$0.05B |
2.15% |
| 2021-12-31 |
$0.00B |
$0.06B |
6.56% |
| 2021-09-30 |
$-0.02B |
$0.04B |
-38.20% |
| 2021-06-30 |
$-0.03B |
$0.04B |
-55.67% |
| 2021-03-31 |
$-0.03B |
$0.05B |
-47.06% |
| 2020-12-31 |
$-0.03B |
$0.05B |
-48.13% |
| 2020-09-30 |
$-0.03B |
$0.06B |
-49.59% |
| 2020-06-30 |
$-0.03B |
$0.07B |
-45.90% |
| 2020-03-31 |
$-0.03B |
$0.07B |
-44.64% |
| 2019-12-31 |
$-0.03B |
$0.05B |
-44.44% |
| 2019-09-30 |
$-0.03B |
$0.06B |
-50.63% |
| 2019-06-30 |
$-0.03B |
$0.06B |
-49.01% |
| 2019-03-31 |
$-0.03B |
$0.06B |
-47.14% |
| 2018-12-31 |
$-0.03B |
$0.06B |
-42.86% |
| 2018-03-31 |
$-0.01B |
$0.09B |
-126.32% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.020B |
$0.012B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
